Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates

Canadian Journal of Infectious Diseases

Volumn 8, Issue 3, 1997, Pages 147-153

  Forward, Kevin R ^a   Low, Donald E ^b   Laverdiere, Michel ^b   Rennie, Robert ^b   Simor, Andrew E ^b   Franks, Patricia A ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

Canadian; Piperacillin tazobactam; Resistance; Susceptibility

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CLAVULANIC ACID; ERYTHROMYCIN; GENTAMICIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; VANCOMYCIN;

AEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CANADA; COMMUNITY HOSPITAL; DRUG MIXTURE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HOSPITAL LABORATORY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TEACHING HOSPITAL;

EID: 0030837082     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/632673     Document Type: Article

References (27)

1. Bush K, Jacob GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
2. Bryson HM, Brogden RN. Piperacillin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.
3. Baron EJ, Jones RN. National survey of the in vitro spectrum of pipercillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centres. Diagn Microbiol Infect Dis 1995;21:141-51.
4. National Committee for Clinical Laboratory Standards (NCCLS) Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A5. Villanova: NCCLS, 1993.
5. National Committee for Clinical Laboratory Standards (NCCLS) Performance Standards For Antimicrobial Susceptibility Testing: 5th Informational Supplement, M100-S5. Villanova: NCCLS, 1994.
6. Jarlier V, Nicholas MH, Fournier G, Philippon A. Extended broad-spectrum β-Lactamases conferring transferable resistance to newer β-Lactam antibiotics in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
7. Shlaes DM, Baughman R, Boylen CT, et al. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection. J Antimicrob Chemother 1994;3:565-77.
8. Sweet RL, Roy S, Faro S, et al. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol 1993;83:280-5.
9. Tan JS, Wishnow RM, Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicentre study of piperacillin/tazobactam versus ticarcillin/clavulanate. Antimicrob Agents Chemother 1993;37:1580-6.
10. Moulton Y, Leroy O, Beuscart C. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;31(Suppl A):87-95.
11. Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteremia. J Antimicrob Chemother 1993;31(Suppl A):97-104.
12. Gorbach SL. Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive Care Med 1994;20:S27-34.
13. Charbonneau P. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. Intensive Care Med 1994;20:S43-8.
14. Nowe P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 1994;20:S39-42.
15. Brismar D, Maimborg AS, Tunevall G, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-74.
16. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infection. Surg Gynecol Obstet 1993;176:255-61.
17. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-52.
18. Micozzi A, Nucci M, Venditti M, et al. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/tiecoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993;12:1-8.
19. Akova M, Yang Y, Libermore DM. Interactions of tazobactam and clavulanate with inducibly and constitutively ex́pressed class I beta-lactamases. J Antimicrob Chemother 1990;25:199-208.
20. Scriver SR, Canadian Antimicrobial Resistant Study Group, Low DE. Comparative activity of several antimicrobial agents against nosocomial Gram-negative rods isolated across Canada. Can J Infect Dis 1995;6:76-82.
21. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended spectrum beta-Lactamases at a Massachusetts chronic care facility. Antimicrob Agents Chemother 1990;4:2193-9.
22. Quinn JP, Miyashiro D, Sahm D et al. Novel plasmed-mediated β-Lactamase (TEM-10) conferring resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989;33:1451-6.
23. Hupkova M, Blahova J, Babalova M, Kromery V Sr, Kralikova K. Transferable resistance to cefotaxime in nosocomial Klebsiella pneumoniae and Escherichia coll strains due to their production of extended-spectrum beta-lactamase in Slovakia. J Chemother 1995;7:16-20.
24. Bradford TA, Urban C, Jaiswal A et al. SHB-7, a novel cefotaxime-hydrolyzing beta-lactamase identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 1995;39:899-905.
25. Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA, Bush K. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: Identification of the extended spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate. Antimicrob Agents Chemother 1994;38:761-866.
26. Conly JM, Shafran SD. Confronting antibiotic-resistant organisms - A Canadian perspective. Can J Infect Dis 1995;6:130-2.
27. Nicolle LE. Antimicrobial resistance: A journey without end. Can J Infect Dis 1995;6:71-2.